TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: review decision - July 2014
Review of TA68; The clinical effectiveness and cost effectiveness of photodynamic therapy for age-related macular degeneration, TA155; Pegaptanib and ranibizumab for the treatment of age-related macular degeneration, and TA294; Aflibercept solution for injection for treating wet age related macular degeneration
The Institute proposed that TA68, TA155 and TA294 should be transferred to the ‘static guidance list’.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.
TA68, TA155 and TA294 will therefore be moved to the static list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: 13 July 2014